What You Ought to Know:
– Tempus AI, Inc., a know-how firm centered on advancing precision drugs with AI, has acquired Paige, an AI firm specializing in digital pathology.
– The acquisition, valued at $81.25M, paid predominantly in Tempus frequent inventory, is a strategic transfer to develop Tempus’s dataset, increase its technical crew, and strengthen its place in digital pathology.
A Complete Dataset and Pioneering AI Purposes
Since its founding in 2017, Paige has developed and deployed a number of AI purposes, together with the primary FDA-cleared AI utility in pathology. These instruments assist researchers and pathologists detect most cancers extra successfully, enabling care groups to make extra exact and knowledgeable therapy selections.
Paige has constructed its merchandise utilizing a dataset of just about 7 million digitized pathology slide photographs and their related medical and molecular knowledge. The information, which is stripped of affected person identifiers to guard privateness, spans 45 nations and features a numerous vary of genders, races, ethnicities, and areas. Leveraging this complete dataset, Paige has additionally created the primary million-slide basis mannequin for most cancers, which helps researchers and life sciences firms higher perceive pathology knowledge and advance drug discovery and growth. With this acquisition, Tempus can also be assuming Paige’s remaining dedication below its current Microsoft Azure cloud companies settlement.
In accordance with Eric Lefkofsky, Founder and CEO of Tempus, the acquisition will “considerably speed up” the corporate’s efforts to construct the biggest basis mannequin ever created in oncology. He believes that each the Paige crew, with its deep generative AI expertise, and the dataset it has constructed might be catalytic to all of Tempus’s AI initiatives.
